Cellectis S.A. Share Price Today: Live Updates & Key Insights

Cellectis S.A. share price today is $3.35, up -4.02%. The stock opened at $3.37 against the previous close of $3.48, with an intraday high of $3.42 and low of $3.26.

Cellectis S.A. Share Price Chart

Cellectis S.A.

us-stock
To Invest in {{usstockname}}
us-stock

Cellectis S.A. Share Price Performance

$3.35 -0.0402(-4.02%) CLLS at 23 Mar 2026 12:28 PM Biotechnology
Lowest Today 3.26
Highest Today 3.42
Today’s Open 3.37
Prev. Close 3.48
52 Week High 5.48
52 Week Low 1.10
Day’s Range: Low 3.26 High 3.42
52-Week Range: Low 1.10 High 5.48
1 day return -
1 Week return -3.72
1 month return -15.57
3 month return -27.89
6 month return -7.43
1 year return +157.47
3 year return +68.84
5 year return -84.47
10 year return -

Cellectis S.A. Institutional Holdings

B Group, Inc 3.26

Long Focus Capital Management, LLC 2.77

UBS Lux Dgtl Hlth Eq Fd seeding P acc 1.30

iShares Biotechnology ETF 0.35

Macquarie Group Ltd 0.23

Nomura Healthcare Fund Class I 0.23

Galileo - Biotech Innovation Fund S USD 0.22

Marshall Wace Asset Management Ltd 0.18

Citadel Advisors Llc 0.09

Ox Capital Dynamic Asia X USD Unhdgd Acc 0.09

Morgan Stanley - Brokerage Accounts 0.09

LPL Financial Corp 0.08

Susquehanna International Group, LLP 0.05

BNP Paribas Arbitrage, SA 0.04

Prisma Cube 0.03

UBS Group AG 0.03

Virtu Financial LLC 0.03

Delaney Dennis R 0.02

P & S Renditefonds T 0.01

Rhumbline Advisers 0.01

First Affirmative Financial Network 0.01

JPMorgan Chase & Co 0.01

Global Retirement Partners, LLC. 0.01

HARBOUR INVESTMENTS, INC. 0.00

NATIONAL BANK OF CANADA /FI/ 0.00

Wells Fargo & Co 0.00

Quadrant Capital Group LLC 0.00

Cellectis S.A. Market Status

Strong Buy: 1

Buy: 2

Hold: 2

Sell: 0

Strong Sell: 0

Cellectis S.A. Fundamentals

Market Cap 335.97 M

PB Ratio 3.3438

PE Ratio 0.0

Enterprise Value 245.03 M

Total Assets 383.54 M

Volume 103093

Cellectis S.A. Company Financials

Annual Revenue FY23:16496000 16.5M, FY22:19171000 19.2M, FY21:73949000 73.9M, FY20:73949000 73.9M, FY19:15190000 15.2M

Annual Profit FY23:15235000 15.2M, FY22:17399000 17.4M, FY21:37674000 37.7M, FY20:37674000 37.7M, FY19:3798000 3.8M

Annual Net worth FY23:-85010000 -85.0M, FY22:-98688000 -98.7M, FY21:-86280000 -86.3M, FY20:-72571000 -72.6M, FY19:-90686000 -90.7M

Quarterly Revenue Q3/2025:35172000 35.2M, Q2/2025:16725000 16.7M, Q1/2025:10655000 10.7M, Q3/2024:16200000 16.2M, Q2/2024:8061000 8.1M

Quarterly Profit Q3/2025:32815000 32.8M, Q2/2025:14300000 14.3M, Q1/2025:8640000 8.6M, Q3/2024:11480000 11.5M, Q2/2024:3333000 3.3M

Quarterly Net worth Q3/2025:589000 0.6M, Q2/2025:-23735000 -23.7M, Q1/2025:-18128000 -18.1M, Q3/2024:-23056000 -23.1M, Q2/2024:-25270000 -25.3M

About Cellectis S.A. & investment objective

Company Information Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company was founded in 1999 and is headquartered in Paris, France.

Organisation Biotechnology

Employees 216

Industry Biotechnology

CEO Dr. Andre Choulika Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Cellectis S.A. FAQs

What is the share price of Cellectis S.A. today?

The current share price of Cellectis S.A. is $3.35.

Can I buy Cellectis S.A. shares in India?

Yes, Indian investors can buy Cellectis S.A. shares by opening an international trading and demat account with Motilal Oswal.

How to buy Cellectis S.A. shares in India?

You can easily invest in Cellectis S.A. shares from India by:

Can I buy fractional shares of Cellectis S.A.?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Cellectis S.A.?

Cellectis S.A. has a market cap of $335.97 M.

In which sector does Cellectis S.A. belong?

Cellectis S.A. operates in the Biotechnology sector.

What documents are required to invest in Cellectis S.A. stocks?

To invest, you typically need:

What is the PE and PB ratio of Cellectis S.A.?

The PE ratio of Cellectis S.A. is N/A and the PB ratio is 3.34.